Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
See All Experts
featured
Published in Oncology and
1 other channel

Expert Opinion / Interview · September 22, 2016

HER2 Biosimilars in Clinical Practice: An Interview With Dr. William Gradishar

Farzanna Haffizulla MD, FACP, FAMWA
William Gradishar MD, FACP

 

 Save  Recommend
 Share

Additional Info

  1. Rugo HS, Barve A, Waller CF, et al. Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract LBA503.

Further Reading

Most Watched This Week

Related Videos